Author: Dino Mustafić

September 20, 2021 Off

Santhera nets CHF 45 Million in funding

By Dino Mustafić

Santhera Pharmaceuticals has announced a cahs boost with an oversubscribed equity financing of CHF 20 million, a placement of private convertible bonds of CHF 15 million and upsizing of an existing financing arrangement of up to CHF 10 million.

September 13, 2021 Off

USFDA accepts Novartis’ tislelizumab for people with esophageal cancer

By Dino Mustafić

Novartis got an acceptance by the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for anti-PD-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received prior systemic therapy.

July 19, 2021 Off

Lonza and CN Bio in new distribution agreement

By Dino Mustafić

Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS)